Prilosec OTC Review: Two Advisory Cmte. Members Weigh In Without Voting
Executive Summary
An upcoming publication by FDA's Gastrointestinal Drugs Advisory Committee chairman will suggest a potential link between proton pump inhibitor therapy and the proliferation of pre-existing esophageal adenocarcinoma
You may also be interested in...
Prilosec To Remain Rx Pending OTC Label Revisions, Patient Study – Cmte.
AstraZeneca/Procter & Gamble's Prilosec should remain a prescription-only medication pending revisions to the proposed OTC label, a joint FDA advisory committee suggested June 21
Prilosec GERD Indication Suitability For OTC Use Debated By Advisory Cmte.
Gastroesophageal reflux disease is appropriate for OTC treatment, but AstraZeneca/Procter & Gamble's NDA to switch Prilosec OTC is not approvable, FDA's Nonprescription and Gastrointestinal Drugs Advisory Committees voted at a joint meeting Oct. 20.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011